Glycolipid derivatives of vancomycin are active against vancomycin-resistant bacterial strains, and thus provide a starting point for the design of better antibiotics. Using a combination of chemical, biochemical, and genetic approaches, this laboratory has obtained evidence that these vancomycin derivatives have two different modes of action. One mode of action is shared with the parent compound, vancomycin, and involves binding to the peptide termini of peptidoglcyan precurosors, sterically blocking the enzymes involved in peptidoglycan synthesis. The second mode of action, attributable to the functionalized carbohydrate portion of the molecules, also involves inhibition of peptidoglycan synthesizing enzymes, but does not depend on peptide binding. Instead, the functionalized carbohydrates directly inhibit bacterial transglycosylases. This latter mode of action may explain the activity against resistant bacterial strains. If so, one might predict that better antibiotics can be made by coupling a compound having transglycosylase inhibitory activity to a compound having peptide binding activity.
The first aim of this grant is to investigate the requirements for structural activity of the best transglycosylase inhibitor currently known, the pentasaccharide moenomycin A.
The second aim i s to explore the potential of hybrid antibiotics consisting of a peptide binding element coupled to a transglycosylase inhibitory element.
The third aim i nvolves developing a better understanding of the regulatory networks involved in transglycosylation by probing bacterial strains with the compounds that are produced. Since transglycosylation is important for both growth and division of bacterial cells, understanding these networks may shed light on fundamental aspects of bacterial metabolism.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Medicinal Chemistry Study Section (MCHA)
Program Officer
Schwab, John M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Princeton University
Schools of Arts and Sciences
United States
Zip Code
Bertani, Blake R; Taylor, Rebecca J; Nagy, Emma et al. (2018) A cluster of residues in the lipopolysaccharide exporter that selects substrate variants for transport to the outer membrane. Mol Microbiol 109:541-554
Mandler, Michael D; Baidin, Vadim; Lee, James et al. (2018) Novobiocin Enhances Polymyxin Activity by Stimulating Lipopolysaccharide Transport. J Am Chem Soc 140:6749-6753
Zheng, Sanduo; Sham, Lok-To; Rubino, Frederick A et al. (2018) Structure and mutagenic analysis of the lipid II flippase MurJ from Escherichia coli. Proc Natl Acad Sci U S A 115:6709-6714
Rubino, Frederick A; Kumar, Sujeet; Ruiz, Natividad et al. (2018) Membrane Potential Is Required for MurJ Function. J Am Chem Soc 140:4481-4484
Schaefer, Kaitlin; Owens, Tristan W; Kahne, Daniel et al. (2018) Substrate Preferences Establish the Order of Cell Wall Assembly in Staphylococcus aureus. J Am Chem Soc 140:2442-2445
Sherman, David J; Xie, Ran; Taylor, Rebecca J et al. (2018) Lipopolysaccharide is transported to the cell surface by a membrane-to-membrane protein bridge. Science 359:798-801
Xie, Ran; Taylor, Rebecca J; Kahne, Daniel (2018) Outer Membrane Translocon Communicates with Inner Membrane ATPase To Stop Lipopolysaccharide Transport. J Am Chem Soc 140:12691-12694
Qiao, Yuan; Srisuknimit, Veerasak; Rubino, Frederick et al. (2017) Lipid II overproduction allows direct assay of transpeptidase inhibition by ?-lactams. Nat Chem Biol 13:793-798
Schaefer, Kaitlin; Matano, Leigh M; Qiao, Yuan et al. (2017) In vitro reconstitution demonstrates the cell wall ligase activity of LCP proteins. Nat Chem Biol 13:396-401
May, Janine M; Owens, Tristan W; Mandler, Michael D et al. (2017) The Antibiotic Novobiocin Binds and Activates the ATPase That Powers Lipopolysaccharide Transport. J Am Chem Soc 139:17221-17224

Showing the most recent 10 out of 59 publications